Please assess the completion status of the following clinical trial:

Trial Title: Endometrial Injury Versus Luteal Phase Support in Intrauterine Insemination Cycles

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients are undergone intrauterine insemination with gonadotropin stimulation~* Bilateral patent fallopian tubes revealed by hysterosalpingography or laparoscopy~* After semen preparation for intrauterine insemination, total progressive sperm count \> 5 million~Exclusion Criteria:~* endocrin or metabolic disorders,~* uterine factor,~* pelvic inflammatory disease,~* women with basal follicle-stimulating hormone (FSH) level \>15 IU/mL,~* body mass index (BMI) ≥ 35 kg/m2,~* age ≥ 40 and \< 18 years,

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Endometrial Injury (Type: ACTIVE_COMPARATOR): Endometrial injury in luteal phase of preceding IUI cycle
- Luteal Phase Support (Type: ACTIVE_COMPARATOR): Luteal phase support with progesterone (Crinone® %8 vaginal progesterone gel) in IUI cycle Vaginal progesterone gel is administered from second day after insemination until pregnancy testing and is continued in the presence of pregnancy until the 12 weeks of pregnancy.
- Control group (Type: NO_INTERVENTION): Only IUI

Based on this trial design, predict the completion outcome and termination type (if applicable).